APO Research
Talk to an analyst

APO RESEARCH · REPORT

Genetically Modified Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Genetically Modified Drug Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchGenetically Modified Drug Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Genetically Modified Drug Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Genetically Modified Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Genetically Modified Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Genetically Modified Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Genetically Modified Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Genetically Modified Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Genetically Modified Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Genetically Modified Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Genetically Modified Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Genetically Modified Drug market include Takeda, Sanofi, Johnson & Johnson, Novartis, Merck & Co., Roche, Eli Lilly, Pfizer and GlaxoSmithKline, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Genetically Modified Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Genetically Modified Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Genetically Modified Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Genetically Modified Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Genetically Modified Drug Segment by Company

Takeda

Sanofi

Johnson & Johnson

Novartis

Merck & Co.

Roche

Eli Lilly

Pfizer

GlaxoSmithKline

Baxter

Amgen

Pharming Group NV

LFB Biotechnologies SA

F. Hoffmann-La Roche

Abbott Laboratories

Genetically Modified Drug Segment by Type

Transgenic Animal

Transgenic Plant

Genetically Modified Drug Segment by Application

Hospital

Clinic

Genetically Modified Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Genetically Modified Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Genetically Modified Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Genetically Modified Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Genetically Modified Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Genetically Modified Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Genetically Modified Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Genetically Modified Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Genetically Modified Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Genetically Modified Drug industry.

Chapter 3: Detailed analysis of Genetically Modified Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Genetically Modified Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Genetically Modified Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Genetically Modified Drug Industry Trends Table 2. Genetically Modified Drug Industry Drivers Table 3. Genetically Modified Drug Industry Opportunities and Challenges Table 4. Genetically Modified Drug Industry Restraints Table 5. Global Genetically Modified Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Genetically Modified Drug Revenue Share by Company (2021-2026) Table 7. Global Genetically Modified Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Genetically Modified Drug Sales Volume Share by Company (2021-2026) Table 9. Global Genetically Modified Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Genetically Modified Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Genetically Modified Drug Key Company Manufacturing Base & Headquarters Table 12. Global Genetically Modified Drug Company, Product Type & Application Table 13. Global Genetically Modified Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Genetically Modified Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Transgenic Animal Table 18. Significant Companies of Transgenic Plant Table 19. Global Genetically Modified Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Genetically Modified Drug Sales Volume by Type (2021-2026) & (k units) Table 21. Global Genetically Modified Drug Sales Volume by Type (2027-2032) & (k units) Table 22. Global Genetically Modified Drug Sales Volume Share by Type (2021-2026) Table 23. Global Genetically Modified Drug Sales Volume Share by Type (2027-2032) Table 24. Global Genetically Modified Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Genetically Modified Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Genetically Modified Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Genetically Modified Drug Sales Value Share by Type (2021-2026) Table 28. Global Genetically Modified Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Genetically Modified Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Genetically Modified Drug Sales Volume by Application (2021-2026) & (k units) Table 33. Global Genetically Modified Drug Sales Volume by Application (2027-2032) & (k units) Table 34. Global Genetically Modified Drug Sales Volume Share by Application (2021-2026) Table 35. Global Genetically Modified Drug Sales Volume Share by Application (2027-2032) Table 36. Global Genetically Modified Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Genetically Modified Drug Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Genetically Modified Drug Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Genetically Modified Drug Sales Value Share by Application (2021-2026) Table 40. Global Genetically Modified Drug Sales Value Share by Application (2027-2032) Table 41. Global Genetically Modified Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Genetically Modified Drug Sales by Region (2021-2026) & (k units) Table 43. Global Genetically Modified Drug Sales Market Share by Region (2021-2026) Table 44. Global Genetically Modified Drug Sales by Region (2027-2032) & (k units) Table 45. Global Genetically Modified Drug Sales Market Share by Region (2027-2032) Table 46. Global Genetically Modified Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Genetically Modified Drug Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Genetically Modified Drug Sales Value Share by Region (2021-2026) Table 49. Global Genetically Modified Drug Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Genetically Modified Drug Sales Value Share by Region (2027-2032) Table 51. Global Genetically Modified Drug Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Genetically Modified Drug Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Genetically Modified Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Genetically Modified Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Genetically Modified Drug Sales by Country (2021-2026) & (k units) Table 56. Global Genetically Modified Drug Sales Market Share by Country (2021-2026) Table 57. Global Genetically Modified Drug Sales by Country (2027-2032) & (k units) Table 58. Global Genetically Modified Drug Sales Market Share by Country (2027-2032) Table 59. Global Genetically Modified Drug Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Genetically Modified Drug Sales Value Market Share by Country (2021-2026) Table 61. Global Genetically Modified Drug Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Genetically Modified Drug Sales Value Market Share by Country (2027-2032) Table 63. Takeda Company Information Table 64. Takeda Business Overview Table 65. Takeda Genetically Modified Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Takeda Genetically Modified Drug Product Portfolio Table 67. Takeda Recent Development Table 68. Sanofi Company Information Table 69. Sanofi Business Overview Table 70. Sanofi Genetically Modified Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Sanofi Genetically Modified Drug Product Portfolio Table 72. Sanofi Recent Development Table 73. Johnson & Johnson Company Information Table 74. Johnson & Johnson Business Overview Table 75. Johnson & Johnson Genetically Modified Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Johnson & Johnson Genetically Modified Drug Product Portfolio Table 77. Johnson & Johnson Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis Genetically Modified Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Novartis Genetically Modified Drug Product Portfolio Table 82. Novartis Recent Development Table 83. Merck & Co. Company Information Table 84. Merck & Co. Business Overview Table 85. Merck & Co. Genetically Modified Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Merck & Co. Genetically Modified Drug Product Portfolio Table 87. Merck & Co. Recent Development Table 88. Roche Company Information Table 89. Roche Business Overview Table 90. Roche Genetically Modified Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Roche Genetically Modified Drug Product Portfolio Table 92. Roche Recent Development Table 93. Eli Lilly Company Information Table 94. Eli Lilly Business Overview Table 95. Eli Lilly Genetically Modified Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Eli Lilly Genetically Modified Drug Product Portfolio Table 97. Eli Lilly Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Genetically Modified Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Pfizer Genetically Modified Drug Product Portfolio Table 102. Pfizer Recent Development Table 103. GlaxoSmithKline Company Information Table 104. GlaxoSmithKline Business Overview Table 105. GlaxoSmithKline Genetically Modified Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. GlaxoSmithKline Genetically Modified Drug Product Portfolio Table 107. GlaxoSmithKline Recent Development Table 108. Baxter Company Information Table 109. Baxter Business Overview Table 110. Baxter Genetically Modified Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Baxter Genetically Modified Drug Product Portfolio Table 112. Baxter Recent Development Table 113. Amgen Company Information Table 114. Amgen Business Overview Table 115. Amgen Genetically Modified Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Amgen Genetically Modified Drug Product Portfolio Table 117. Amgen Recent Development Table 118. Pharming Group NV Company Information Table 119. Pharming Group NV Business Overview Table 120. Pharming Group NV Genetically Modified Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Pharming Group NV Genetically Modified Drug Product Portfolio Table 122. Pharming Group NV Recent Development Table 123. LFB Biotechnologies SA Company Information Table 124. LFB Biotechnologies SA Business Overview Table 125. LFB Biotechnologies SA Genetically Modified Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. LFB Biotechnologies SA Genetically Modified Drug Product Portfolio Table 127. LFB Biotechnologies SA Recent Development Table 128. F. Hoffmann-La Roche Company Information Table 129. F. Hoffmann-La Roche Business Overview Table 130. F. Hoffmann-La Roche Genetically Modified Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. F. Hoffmann-La Roche Genetically Modified Drug Product Portfolio Table 132. F. Hoffmann-La Roche Recent Development Table 133. Abbott Laboratories Company Information Table 134. Abbott Laboratories Business Overview Table 135. Abbott Laboratories Genetically Modified Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. Abbott Laboratories Genetically Modified Drug Product Portfolio Table 137. Abbott Laboratories Recent Development Table 138. Key Raw Materials Table 139. Raw Materials Key Suppliers Table 140. Genetically Modified Drug Distributors List Table 141. Genetically Modified Drug Customers List Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Genetically Modified Drug Product Image Figure 2. Global Genetically Modified Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Genetically Modified Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Genetically Modified Drug Sales (2021-2032) & (k units) Figure 5. Global Genetically Modified Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Genetically Modified Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Transgenic Animal Image Figure 10. Transgenic Plant Image Figure 11. Global Genetically Modified Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Genetically Modified Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Genetically Modified Drug Sales Volume Share by Type (2021-2032) Figure 14. Global Genetically Modified Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Genetically Modified Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Genetically Modified Drug Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Genetically Modified Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Genetically Modified Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Genetically Modified Drug Sales Volume Share by Application (2021-2032) Figure 22. Global Genetically Modified Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Genetically Modified Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Genetically Modified Drug Sales Value Share by Application (2021-2032) Figure 25. Global Genetically Modified Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Genetically Modified Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Genetically Modified Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Genetically Modified Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Genetically Modified Drug Sales Value (2021-2032) & (US$ Million) Figure 30. North America Genetically Modified Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Genetically Modified Drug Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Genetically Modified Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Genetically Modified Drug Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Genetically Modified Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Genetically Modified Drug Sales Value (2021-2032) & (US$ Million) Figure 36. South America Genetically Modified Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Genetically Modified Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Genetically Modified Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Genetically Modified Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Genetically Modified Drug Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Genetically Modified Drug Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Transgenic Animal
  • Transgenic Plant
Applications
  • Hospital
  • Clinic
Companies covered
  • Takeda
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck & Co.
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Baxter
  • Amgen
  • Pharming Group NV
  • LFB Biotechnologies SA
  • F. Hoffmann-La Roche
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Genetically Modified Drug Sales Value (2021-2032)
  4. 1.2.2 Global Genetically Modified Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Genetically Modified Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Genetically Modified Drug Market Dynamics
  1. 2.1 Genetically Modified Drug Industry Trends
  2. 2.2 Genetically Modified Drug Industry Drivers
  3. 2.3 Genetically Modified Drug Industry Opportunities and Challenges
  4. 2.4 Genetically Modified Drug Industry Restraints
3 Genetically Modified Drug Market by Company
  1. 3.1 Global Genetically Modified Drug Company Revenue Ranking in 2025
  2. 3.2 Global Genetically Modified Drug Revenue by Company (2021-2026)
  3. 3.3 Global Genetically Modified Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Genetically Modified Drug Average Price by Company (2021-2026)
  5. 3.5 Global Genetically Modified Drug Company Ranking (2024-2026)
  6. 3.6 Global Genetically Modified Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Genetically Modified Drug Company Product Type and Application
  8. 3.8 Global Genetically Modified Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Genetically Modified Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Genetically Modified Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Genetically Modified Drug Market by Type
  1. 4.1 Genetically Modified Drug Type Introduction
  2. 4.1.1 Transgenic Animal
  3. 4.1.2 Transgenic Plant
  4. 4.2 Global Genetically Modified Drug Sales Volume by Type
  5. 4.2.1 Global Genetically Modified Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Genetically Modified Drug Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Genetically Modified Drug Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Genetically Modified Drug Sales Value by Type
  9. 4.3.1 Global Genetically Modified Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Genetically Modified Drug Sales Value by Type (2021-2032)
  11. 4.3.3 Global Genetically Modified Drug Sales Value Share by Type (2021-2032)
5 Genetically Modified Drug Market by Application
  1. 5.1 Genetically Modified Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Genetically Modified Drug Sales Volume by Application
  5. 5.2.1 Global Genetically Modified Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Genetically Modified Drug Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Genetically Modified Drug Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Genetically Modified Drug Sales Value by Application
  9. 5.3.1 Global Genetically Modified Drug Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Genetically Modified Drug Sales Value by Application (2021-2032)
  11. 5.3.3 Global Genetically Modified Drug Sales Value Share by Application (2021-2032)
6 Genetically Modified Drug Regional Sales and Value Analysis
  1. 6.1 Global Genetically Modified Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Genetically Modified Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Genetically Modified Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Genetically Modified Drug Sales by Region (2027-2032)
  5. 6.3 Global Genetically Modified Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Genetically Modified Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Genetically Modified Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Genetically Modified Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Genetically Modified Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Genetically Modified Drug Sales Value (2021-2032)
  12. 6.6.2 North America Genetically Modified Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Genetically Modified Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Genetically Modified Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Genetically Modified Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Genetically Modified Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Genetically Modified Drug Sales Value (2021-2032)
  21. 6.9.2 South America Genetically Modified Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Genetically Modified Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Genetically Modified Drug Sales Value Share by Country, 2025 VS 2032
7 Genetically Modified Drug Country-level Sales and Value Analysis
  1. 7.1 Global Genetically Modified Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Genetically Modified Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Genetically Modified Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Genetically Modified Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Genetically Modified Drug Sales by Country (2027-2032)
  6. 7.4 Global Genetically Modified Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Genetically Modified Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Genetically Modified Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Genetically Modified Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Genetically Modified Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Genetically Modified Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Genetically Modified Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Genetically Modified Drug Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Genetically Modified Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Genetically Modified Drug Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Genetically Modified Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Genetically Modified Drug Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Genetically Modified Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Genetically Modified Drug Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck & Co.
  26. 8.5.1 Merck & Co. Company Information
  27. 8.5.2 Merck & Co. Business Overview
  28. 8.5.3 Merck & Co. Genetically Modified Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck & Co. Genetically Modified Drug Product Portfolio
  30. 8.5.5 Merck & Co. Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Genetically Modified Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Roche Genetically Modified Drug Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Eli Lilly
  38. 8.7.1 Eli Lilly Company Information
  39. 8.7.2 Eli Lilly Business Overview
  40. 8.7.3 Eli Lilly Genetically Modified Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly Genetically Modified Drug Product Portfolio
  42. 8.7.5 Eli Lilly Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Genetically Modified Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Genetically Modified Drug Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 GlaxoSmithKline
  50. 8.9.1 GlaxoSmithKline Company Information
  51. 8.9.2 GlaxoSmithKline Business Overview
  52. 8.9.3 GlaxoSmithKline Genetically Modified Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline Genetically Modified Drug Product Portfolio
  54. 8.9.5 GlaxoSmithKline Recent Developments
  55. 8.10 Baxter
  56. 8.10.1 Baxter Company Information
  57. 8.10.2 Baxter Business Overview
  58. 8.10.3 Baxter Genetically Modified Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Baxter Genetically Modified Drug Product Portfolio
  60. 8.10.5 Baxter Recent Developments
  61. 8.11 Amgen
  62. 8.11.1 Amgen Company Information
  63. 8.11.2 Amgen Business Overview
  64. 8.11.3 Amgen Genetically Modified Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Amgen Genetically Modified Drug Product Portfolio
  66. 8.11.5 Amgen Recent Developments
  67. 8.12 Pharming Group NV
  68. 8.12.1 Pharming Group NV Company Information
  69. 8.12.2 Pharming Group NV Business Overview
  70. 8.12.3 Pharming Group NV Genetically Modified Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Pharming Group NV Genetically Modified Drug Product Portfolio
  72. 8.12.5 Pharming Group NV Recent Developments
  73. 8.13 LFB Biotechnologies SA
  74. 8.13.1 LFB Biotechnologies SA Company Information
  75. 8.13.2 LFB Biotechnologies SA Business Overview
  76. 8.13.3 LFB Biotechnologies SA Genetically Modified Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 LFB Biotechnologies SA Genetically Modified Drug Product Portfolio
  78. 8.13.5 LFB Biotechnologies SA Recent Developments
  79. 8.14 F. Hoffmann-La Roche
  80. 8.14.1 F. Hoffmann-La Roche Company Information
  81. 8.14.2 F. Hoffmann-La Roche Business Overview
  82. 8.14.3 F. Hoffmann-La Roche Genetically Modified Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 F. Hoffmann-La Roche Genetically Modified Drug Product Portfolio
  84. 8.14.5 F. Hoffmann-La Roche Recent Developments
  85. 8.15 Abbott Laboratories
  86. 8.15.1 Abbott Laboratories Company Information
  87. 8.15.2 Abbott Laboratories Business Overview
  88. 8.15.3 Abbott Laboratories Genetically Modified Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Abbott Laboratories Genetically Modified Drug Product Portfolio
  90. 8.15.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Genetically Modified Drug Value Chain Analysis
  2. 9.1.1 Genetically Modified Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Genetically Modified Drug Sales Mode & Process
  6. 9.2 Genetically Modified Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Genetically Modified Drug Distributors
  9. 9.2.3 Genetically Modified Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst